Evidence map›Paper›PMID 23113687›Full record

ReviewImmunology2013

HLA-DM: arbiter conformationis.

Andrea Ferrante

Open access · greenAbstract readReview
In one paragraph

Review in Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Andrea FerranteInstitute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, AK, USA. aferrante@alaska.edu
University of Alaska Fairbanks · US

Funding

The Administrative CoreP20GM103395 · NIGMS · UNIVERSITY OF ALASKA FAIRBANKS · PI BRIAN M BARNES · 2012 to 2026
$66.1M
Epitope selection by HLA-DRR01AI063016 · NIAID · VERSITI WISCONSIN, INC. · PI GORSKI, JACK A · 2005 to 2009
$1.5M
Permissive Specificity in Peptide Binding to HLA-DRR56AI098136 · NIAID · VERSITI WISCONSIN, INC. · PI GORSKI, JACK A · 2012 to 2012
$313k
NIAID NIH HHS R01 AI063016NIAID NIH HHS R01AI63016NIAID NIH HHS R56 AI098136NIGMS NIH HHS P20 GM103395NIGMS NIH HHS P20GM103395
6 · The paper itself

Abstract

The recognition by CD4(+) T cells of peptides bound to class II MHC (MHCII) molecules expressed on the surface of antigen-presenting cells is a key step in the initiation of an adaptive immune response. Presentation of peptides is the outcome of an intracellular selection process occurring in dedicated endosomal compartments involving, among others, an MHCII-like molecule named HLA-DM (DM). The impact of DM on the epitope selection machinery has been known for more than 15 years. However, the mechanism by which DM skews the presented repertoire in favour of kinetically stable complexes has remained elusive. Here, a review of the most recent observations in the field is presented, pointing to the possibility that DM decides the survival of a peptide-MHCII complex (pMHCII) on the basis of its conformational flexibility, which is a function of the 'tightness' of interaction between the peptide and the MHCII at a specific region of the binding site.

Indexed as

Antigen PresentationBinding SitesCD4-Positive T-LymphocytesEndosomesHLA-D AntigensHumansPeptidesStructure-Activity RelationshipHLA-D AntigensHLA-DM antigensPeptides

Identifiers

PMID23113687
PMCPMC3575761
OpenAlexW1975331270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.